What Are New and Experimental Treatments for IMNM?

When standard treatments for Immune-Mediated Necrotizing Myopathy (IMNM)—such as high-dose corticosteroids, intravenous immunoglobulin (IVIG), and conventional immunosuppressants—do not adequately control your symptoms, it can be deeply frustrating and exhausting. If you find yourself in this situation, there is no single universally accepted sequence of next steps. However, specialists have several off-label options and investigational therapies to consider.

Before changing or escalating your treatment, your care team must first determine if your disease is truly “refractory” (resistant to treatment). They will evaluate whether your persistent weakness is caused by ongoing active muscle inflammation or if it is due to other factors, such as fixed muscle damage, weakness from long-term steroid use, or simple deconditioning ^[1]. Escalating immune suppression carries significant risks, so doctors rely on objective markers—like creatine kinase (CK) blood levels, MRI scans, and functional tests—to confirm active disease before making changes ^[2]. Never stop or rapidly reduce your current medications, especially corticosteroids, on your own, as this can be dangerous.

While IMNM is associated with specific autoantibodies (like anti-SRP or anti-HMGCR), these antibodies are only one part of a complex disease process. Lowering antibody levels is a major goal of treatment, but it does not guarantee immediate muscle recovery, and weakness can persist even after inflammation is controlled.

Specialist-Directed and Off-Label Options

When active disease persists despite standard care, specialists may try these individualized approaches:

• Rituximab: This off-label medication targets a specific group of immune cells (CD20-positive B-cells) to reduce the immune system’s attack. In one review of 34 patients who received rituximab after other therapies failed, about 62% showed a clinical response ^[3]. Some small studies suggest it might be used more frequently in the anti-SRP subtype, though responses have also occurred in anti-HMGCR disease ^[4][5]. However, rituximab does not eliminate all antibody-producing cells, and recovery can take weeks to months. Major risks include infusion reactions, an increased risk of severe infections, hepatitis B reactivation, and reduced effectiveness of vaccines ^[6].
• Plasma Exchange (PLEX): Also known as plasmapheresis, this procedure physically filters your blood to remove circulating components, including harmful antibodies ^[7]. It is not a routine treatment but is sometimes used as a temporary “rescue” therapy for severe, rapidly worsening weakness. Evidence for PLEX in IMNM relies mostly on small case reports where it was combined with other drugs, making its specific benefit hard to measure ^[8][9]. It requires specialized vascular access and carries practical risks, including low blood pressure, bleeding, infection, electrolyte imbalances, and the accidental removal of protective antibodies or other medications (like IVIG).
• Combination Therapies: Specialists may sometimes combine medications or use other off-label immunosuppressants, such as tacrolimus or cyclophosphamide ^[10][11]. Evidence for these is limited to very small cohorts. Drugs like cyclophosphamide carry substantial risks, including severe infections, bladder toxicity, and secondary malignancies ^[12].

Investigational Therapies and Clinical Trials

Researchers are actively exploring new pathways. Participating in a clinical trial can offer access to these therapies, but it is important to understand that trials involve unknown risks, strict eligibility criteria, intensive monitoring, and sometimes the possibility of receiving a placebo instead of the active drug.

• FcRn Inhibitors (e.g., Efgartigimod, Nipocalimab): These investigational drugs block a receptor (FcRn) to speed up the body’s breakdown of IgG antibodies ^[13]. In a very small, uncontrolled pilot study of seven patients with refractory IMNM, four patients showed clinical improvement and reduced antibody levels after four weeks of efgartigimod ^[14]. Other small case reports noted CK reductions ^[15][16]. However, these are preliminary, short-term findings that cannot yet prove long-term effectiveness or safety. Because these drugs lower overall protective IgG levels, they may increase your risk of infection. Nipocalimab is also being studied, though IMNM-specific evidence is currently sparse ^[13].
• CAR-T Cell Therapy: This is a highly experimental procedure where a patient’s own T-cells are genetically altered to attack B-cells. Early reports of single IMNM patients receiving CAR-T therapy showed sustained clinical improvement ^[17][18]. However, single cases do not prove general efficacy, and this therapy is only available through highly specialized research programs ^[19]. It carries severe, potentially life-threatening risks, including cytokine-release syndrome (a severe inflammatory response), neurologic toxicity, prolonged immune suppression, and the need for hospitalization.
• Complement Inhibitors: While researchers thought blocking the “complement” system (a part of the immune response) might help, a recent placebo-controlled phase 2 trial of a drug called zilucoplan showed no meaningful benefit in IMNM ^[20][21]. This underscores why rigorous clinical trials are essential.

Urgent Care, Monitoring, and Rehabilitation

Ongoing active IMNM can cause lasting muscle atrophy or fatty replacement, making early, objective monitoring critical ^[22][23]. However, functional recovery takes time, and individualized rehabilitation is a vital part of regaining strength safely.

Because IMNM can affect respiratory and swallowing muscles, you must know when to seek emergency care. Contact your doctor immediately or go to the emergency room if you experience:

• Rapidly worsening weakness
• Shortness of breath, especially when resting or lying down
• Choking, coughing while eating, or an inability to swallow liquids or saliva
• A noticeably weak cough